Section 37 is the residual general-deduction backstop. After s. 30-36 specific deductions, any expenditure that is (a) not personal, (b) not capital, (c) NOT covered by ss. 30-36, AND (d) laid out wholly and exclusively for business is deductible under s. 37(1). The two key carve-outs are: (i) Explanation 1 — illegal / prohibited expenditure (bribery); (ii) Explanation 2 — CSR (FA 2014); (iii) Explanation 3 — pharma freebies (FA 2022).
Historical context / FA amendment trail
Substantively stable since 1961 in its core sub-section (1). Major modern reforms via Explanations: (a) Explanation 1 codified the long-standing common-law illegality bar (CIT v. Piara Singh line). (b) FA 2014 Explanation 2 — CSR not deductible (avoids double-benefit since s. 135 CA 2013 already mandates the spend). (c) FA 2022 Explanation 3 — anti-Apex Laboratories rule on pharma freebies. (d) s. 37(2B) bars political-party-publication advertisement deduction.
Operative consequences
• Wholly-and-exclusively test — purpose of the expenditure must be wholly for business; mixed-purpose disallowed.
• Capital expenditure — excluded (claimed via s. 32 depreciation or specific s. 35-35E amortisations).
• Personal expenses — excluded.
• Illegal / prohibited expenditure — disallowed via Explanation 1.
• CSR — disallowed under Explanation 2 (FA 2014).
• Pharma freebies — disallowed under Explanation 3 (FA 2022).
• Political-party advertisement — disallowed under s. 37(2B).
• Standard burden — assessee must establish purpose, quantum, and that expense is not capital / personal.
Verified cases on point
CIT v. Piara Singh — (1980) 124 ITR 40 (SC)
Holding. Foundational on s. 37(1) and Explanation 1 (illegal expenditure). Held — confiscation of currency notes carried for smuggling is NOT a business loss deductible under s. 37 — losses incurred in the conduct of an illegal activity are NOT laid out wholly and exclusively for legitimate business. The illegality test was statutorily codified by FA 1998 inserting Explanation 1. Authoritative on the illegality bar.
Apex Laboratories P. Ltd. v. DCIT — (2022) 442 ITR 1 (SC) — 2-Judge Bench
Holding. Directly construes s. 37 Explanation 3 (then prospective). Held — expenditure by pharmaceutical companies on freebies / gifts / hospitality to medical practitioners that violates the Medical Council of India Code of Ethics is NOT deductible under s. 37 — it constitutes payment in violation of law / professional conduct rules. Statutorily codified by FA 2022 inserting Explanation 3. Watershed on the boundary of legal-vs-disallowed business expenditure.
Case Laws & Commentary
SECTION 37 — General — Residuary deduction for revenue expenditure laid out wholly and exclusively for purposes of business or profession
Important Case Laws — 1961 Treatise (FA 2026)
Provision in brief: Section 37(1) — residuary catch-all. Allows deduction for any expenditure (not being capital expenditure, personal expenses, or covered by ss. 30-36) laid out or expended wholly and exclusively for the purposes of business / profession. Explanation 1 (since 1998): no allowance for expenditure incurred for any purpose which is an offence or prohibited by law. Explanation 2 (since FA 2014): CSR expenditure under s. 135 Cos Act 2013 is NOT deductible. Explanation 3 (FA 2022 retrospective): expenditure for any purpose that is an offence under any law in India or outside, or which provides any benefit / perquisite to a person in violation of any law/rule/regulation/guideline (e.g., MCI/CDSCO) is NOT deductible.
Section Commentary
Residuary clause — the great catch-all
Section 37(1) is the residuary deduction provision: any expenditure (NOT being capital expenditure, personal expenses, or covered by ss. 30 to 36) laid out or expended WHOLLY AND EXCLUSIVELY for the purposes of business / profession is deductible. The phrase 'wholly and exclusively' has accumulated rich jurisprudence — Sasoon J. David clarifies that 'wholly and exclusively' does NOT mean 'necessarily'. Commercial expediency is the touchstone; the AO cannot disallow merely on quantum (Walchand & Co. (SC)).
Capital-vs-revenue — Empire Jute frame
The single biggest battlefield. Empire Jute (SC 1980) is the watershed: 'enduring benefit' is NOT a conclusive test. The real inquiry is whether the expenditure affects the CAPITAL STRUCTURE or the INCOME-EARNING PROCESS. Mere extension of life or recurring benefit does not make a revenue expense capital. Madras Industrial Investment extends the principle via the 'matching' route — spread of deferred revenue expenditure where benefit endures.
Explanation 1 — illegality bar (FA 1998)
Inserted to neutralise the Piara Singh-line which had allowed deductions in illegal business. Expln 1 bars deduction for expenditure incurred for any purpose which is an offence or prohibited by law. The bar applies even if the assessee's business itself is otherwise legal; the specific expense's purpose must be tested.
Explanation 2 — CSR bar (FA 2014)
Expenditure on activities relating to Corporate Social Responsibility under s. 135 Cos Act 2013 is NOT deductible u/s 37(1). The reasoning: CSR is a statutory levy on profits, not a business expense. Note: some CSR amounts may still flow into s. 35 / 35AC / 35CCA / 80G — separate enabling provisions outside s. 37.
Apex Laboratories (SC 2022) had held that pharma-freebies to medical practitioners — prohibited by IMC Regulations 2002 — are disallowed by Expln 1 (purpose prohibited by law). FA 2022 inserted Expln 3 codifying and extending: (i) any expenditure for any purpose that is an OFFENCE under any law in India OR OUTSIDE INDIA, (ii) any expenditure that provides any benefit / perquisite to a person in violation of any law / rule / regulation / guideline. The reach extends to corporate hospitality, gifts to officials, and any 'soft-bribe' style expenditure even if not technically illegal in India but contrary to a guideline / regulatory norm.
Matching principle — Madras Industrial Investment
Where revenue expenditure yields enduring benefit (e.g., debenture discount over loan life), the SC has allowed pro-rata spread over the benefit period. This is the 'matching principle' applied within s. 37. It mitigates lumpy expense recognition but is restricted to bona fide deferred-revenue items.
Practical fault-lines for the CA
(i) Test every large expense against Empire Jute: capital structure or income-process? (ii) For pharma / medical-device / regulated-sector clients — strict review against Apex Laboratories / Expln 3. (iii) CSR — segregate from regular advertisement / PR (which remain s. 37 deductible). (iv) Foreign-law bribery (FCPA / UK Bribery Act) violations now disallowed in India even if not prosecuted abroad. (v) For demonstrably illegal businesses, Piara Singh's broad freedom is gone — Expln 1/3 cover.
Burden of proof
Initial burden on assessee to establish bona fide business purpose (wholly and exclusively); thereafter burden shifts to Revenue to show one of the bars (capital / personal / Expln 1, 2, 3) applies. Documentary trail (board minutes, invoices, business correspondence) is decisive in scrutiny.
FA 2026 impact: No fresh FA 2026 amendment. FA 2022 had inserted Expln 3 (retrospective) expanding the 'illegal expenditure' bar to cover violations under any law in India or abroad and pharma-freebies to medical practitioners. Read with Apex Laboratories (SC).
Leading Decisions
1. Apex Laboratories (P) Ltd. v. DCIT
Citation: (2022) 442 ITR 1 (SC)
Forum: Supreme Court of India
Facts & Issue: Pharma company gave 'freebies' (gifts, travel, hospitality) to medical practitioners. Indian Medical Council (Professional Conduct) Regulations 2002 — Regulation 6.8 — prohibits doctors from accepting such gifts. Assessee claimed the expense as sales-promotion u/s 37(1).
Held / Ratio: The Supreme Court held that the expenditure is disallowed by Expln 1 to s. 37(1) — it 'is incurred for a purpose which is an offence or prohibited by law'. Even though the prohibition is on the doctor (not the pharma company), the receipt is illegal and the giving abets the violation. The Court used the doctrine that 'one cannot make a profit out of an illegality'. FA 2022 subsequently inserted Expln 3 codifying the position.
Section relevance: Landmark — controls pharma-freebies / similar regulated-recipient gifts under s. 37(1).
2. CIT v. Piara Singh
Citation: (1980) 124 ITR 40 (SC)
Forum: Supreme Court of India
Facts & Issue: Smuggler claimed deduction u/s 37(1) for the value of currency confiscated by customs authorities — treated as a 'business loss' in the illegal business.
Held / Ratio: The Supreme Court allowed the deduction. The Court held that profits of an illegal business are taxable and consequent losses/expenses, including confiscation, are deductible (since the business itself is taxed). However, expenditure that is specifically prohibited (e.g., bribes) remains outside the deduction. Note: Expln 1 to s. 37 (FA 1998) and Expln 3 (FA 2022) now significantly restrict this older line of reasoning for offence-related expenditure.
Section relevance: Foundational on taxation of illegal businesses and the historical scope of s. 37. Constrained by post-1998 Explanations.
3. Empire Jute Co. Ltd. v. CIT
Citation: (1980) 124 ITR 1 (SC)
Forum: Supreme Court of India
Facts & Issue: Jute mill purchased 'loom hours' from competitors. Revenue treated as capital (enduring benefit). Assessee claimed s. 37(1).
Held / Ratio: The Supreme Court allowed the expenditure as revenue. The Court held that 'enduring benefit' is not a conclusive test. What matters is whether the advantage affects the capital structure or the income-earning process. Here, loom hours only enabled more profitable use of existing plant — they did not augment fixed capital. The case is a watershed in the capital-vs-revenue jurisprudence under s. 37.
Section relevance: Cardinal authority on capital-vs-revenue boundary under s. 37(1); restricts the enduring-benefit doctrine.
4. Madras Industrial Investment Corpn. Ltd. v. CIT
Citation: (1997) 225 ITR 802 (SC)
Forum: Supreme Court of India
Facts & Issue: Discount on debentures — single year vs spread over life. Assessee preferred spread.
Held / Ratio: The Supreme Court permitted spread of the discount over the life of the debentures. While generally revenue expenditure is deductible in the year incurred, where the benefit endures and the discount serves the borrowed capital for several years, matching demands spreading. The Court endorsed commercial accountancy principles where the Act is silent.
Section relevance: Cardinal on 'matching' under s. 37(1) — deferred-revenue treatment.
5. Sasoon J. David & Co. (P) Ltd. v. CIT
Citation: (1979) 118 ITR 261 (SC)
Forum: Supreme Court of India
Facts & Issue: 'Wholly and exclusively' — assessee made payments which Revenue alleged were for personal benefit of directors.
Held / Ratio: The Supreme Court held that the phrase 'wholly and exclusively for purposes of business' does NOT mean 'necessarily' — an assessee may incur expenditure that, although not strictly necessary, is commercially expedient. The test is whether the expenditure was made for business purposes, judged from the assessee's vantage point and prevailing commercial considerations.
Section relevance: Defines 'wholly and exclusively' — commercial-expediency reading. Cited routinely in s. 37 litigation.
6. CIT v. Walchand & Co.
Citation: (1967) 65 ITR 381 (SC)
Forum: Supreme Court of India
Facts & Issue: Whether reasonableness of expenditure is a ground for disallowance under s. 37(1).
Held / Ratio: The Supreme Court held that the Income-tax officer cannot disallow expenditure merely on the ground that he considers it excessive or unreasonable. So long as the expenditure is laid out wholly and exclusively for business, the quantum is for the businessman, not the Revenue. (This is now subject to specific anti-avoidance provisions like s. 40A(2) for related-party excess.)
Section relevance: Cardinal on quantum-of-expenditure neutrality of Revenue under s. 37 — subject to specific overrides.
7. CIT v. T.V. Sundaram Iyengar & Sons Ltd.
Citation: (1996) 222 ITR 344 (SC)
Forum: Supreme Court of India
Facts & Issue: Trade advances / deposits no longer claimed by counterparties — written back to P&L. Question whether such write-back is income.
Held / Ratio: The Supreme Court held that where trading liability ceases (lapse, time-bar, write-back) and the amount was originally received in the course of business, the write-back is income. The Court drew on 'change of character' from advance to income. Often cited in conjunction with s. 41(1) and s. 37 disallowances.
Section relevance: Cardinal on character-change of business advances under PGBP framework.
Function in the statutory architecture
Section 37 is the residual general-deduction backstop. After s. 30-36 specific deductions, any expenditure that is (a) not personal, (b) not capital, (c) NOT covered by ss. 30-36, AND (d) laid out wholly and exclusively for business is deductible under s. 37(1). The two key carve-outs are: (i) Explanation 1 — illegal / prohibited expenditure (bribery); (ii) Explanation 2 — CSR (FA 2014); (iii) Explanation 3 — pharma freebies (FA 2022).
Historical context / FA amendment trail
Substantively stable since 1961 in its core sub-section (1). Major modern reforms via Explanations: (a) Explanation 1 codified the long-standing common-law illegality bar (CIT v. Piara Singh line). (b) FA 2014 Explanation 2 — CSR not deductible (avoids double-benefit since s. 135 CA 2013 already mandates the spend). (c) FA 2022 Explanation 3 — anti-Apex Laboratories rule on pharma freebies. (d) s. 37(2B) bars political-party-publication advertisement deduction.
Operative consequences
• Wholly-and-exclusively test — purpose of the expenditure must be wholly for business; mixed-purpose disallowed.
• Capital expenditure — excluded (claimed via s. 32 depreciation or specific s. 35-35E amortisations).
• Personal expenses — excluded.
• Illegal / prohibited expenditure — disallowed via Explanation 1.
• CSR — disallowed under Explanation 2 (FA 2014).
• Pharma freebies — disallowed under Explanation 3 (FA 2022).
• Political-party advertisement — disallowed under s. 37(2B).
• Standard burden — assessee must establish purpose, quantum, and that expense is not capital / personal.
Verified cases on point
CIT v. Piara Singh — (1980) 124 ITR 40 (SC)
Holding. Foundational on s. 37(1) and Explanation 1 (illegal expenditure). Held — confiscation of currency notes carried for smuggling is NOT a business loss deductible under s. 37 — losses incurred in the conduct of an illegal activity are NOT laid out wholly and exclusively for legitimate business. The illegality test was statutorily codified by FA 1998 inserting Explanation 1. Authoritative on the illegality bar.
Apex Laboratories P. Ltd. v. DCIT — (2022) 442 ITR 1 (SC) — 2-Judge Bench
Holding. Directly construes s. 37 Explanation 3 (then prospective). Held — expenditure by pharmaceutical companies on freebies / gifts / hospitality to medical practitioners that violates the Medical Council of India Code of Ethics is NOT deductible under s. 37 — it constitutes payment in violation of law / professional conduct rules. Statutorily codified by FA 2022 inserting Explanation 3. Watershed on the boundary of legal-vs-disallowed business expenditure.
Case Laws & Commentary
SECTION 37 — General — Residuary deduction for revenue expenditure laid out wholly and exclusively for purposes of business or profession
Important Case Laws — 1961 Treatise (FA 2026)
Provision in brief: Section 37(1) — residuary catch-all. Allows deduction for any expenditure (not being capital expenditure, personal expenses, or covered by ss. 30-36) laid out or expended wholly and exclusively for the purposes of business / profession. Explanation 1 (since 1998): no allowance for expenditure incurred for any purpose which is an offence or prohibited by law. Explanation 2 (since FA 2014): CSR expenditure under s. 135 Cos Act 2013 is NOT deductible. Explanation 3 (FA 2022 retrospective): expenditure for any purpose that is an offence under any law in India or outside, or which provides any benefit / perquisite to a person in violation of any law/rule/regulation/guideline (e.g., MCI/CDSCO) is NOT deductible.
Section Commentary
Residuary clause — the great catch-all
Section 37(1) is the residuary deduction provision: any expenditure (NOT being capital expenditure, personal expenses, or covered by ss. 30 to 36) laid out or expended WHOLLY AND EXCLUSIVELY for the purposes of business / profession is deductible. The phrase 'wholly and exclusively' has accumulated rich jurisprudence — Sasoon J. David clarifies that 'wholly and exclusively' does NOT mean 'necessarily'. Commercial expediency is the touchstone; the AO cannot disallow merely on quantum (Walchand & Co. (SC)).
Capital-vs-revenue — Empire Jute frame
The single biggest battlefield. Empire Jute (SC 1980) is the watershed: 'enduring benefit' is NOT a conclusive test. The real inquiry is whether the expenditure affects the CAPITAL STRUCTURE or the INCOME-EARNING PROCESS. Mere extension of life or recurring benefit does not make a revenue expense capital. Madras Industrial Investment extends the principle via the 'matching' route — spread of deferred revenue expenditure where benefit endures.
Explanation 1 — illegality bar (FA 1998)
Inserted to neutralise the Piara Singh-line which had allowed deductions in illegal business. Expln 1 bars deduction for expenditure incurred for any purpose which is an offence or prohibited by law. The bar applies even if the assessee's business itself is otherwise legal; the specific expense's purpose must be tested.
Explanation 2 — CSR bar (FA 2014)
Expenditure on activities relating to Corporate Social Responsibility under s. 135 Cos Act 2013 is NOT deductible u/s 37(1). The reasoning: CSR is a statutory levy on profits, not a business expense. Note: some CSR amounts may still flow into s. 35 / 35AC / 35CCA / 80G — separate enabling provisions outside s. 37.
Explanation 3 — pharma freebies and foreign-law violations (FA 2022, retrospective)
Apex Laboratories (SC 2022) had held that pharma-freebies to medical practitioners — prohibited by IMC Regulations 2002 — are disallowed by Expln 1 (purpose prohibited by law). FA 2022 inserted Expln 3 codifying and extending: (i) any expenditure for any purpose that is an OFFENCE under any law in India OR OUTSIDE INDIA, (ii) any expenditure that provides any benefit / perquisite to a person in violation of any law / rule / regulation / guideline. The reach extends to corporate hospitality, gifts to officials, and any 'soft-bribe' style expenditure even if not technically illegal in India but contrary to a guideline / regulatory norm.
Matching principle — Madras Industrial Investment
Where revenue expenditure yields enduring benefit (e.g., debenture discount over loan life), the SC has allowed pro-rata spread over the benefit period. This is the 'matching principle' applied within s. 37. It mitigates lumpy expense recognition but is restricted to bona fide deferred-revenue items.
Practical fault-lines for the CA
(i) Test every large expense against Empire Jute: capital structure or income-process? (ii) For pharma / medical-device / regulated-sector clients — strict review against Apex Laboratories / Expln 3. (iii) CSR — segregate from regular advertisement / PR (which remain s. 37 deductible). (iv) Foreign-law bribery (FCPA / UK Bribery Act) violations now disallowed in India even if not prosecuted abroad. (v) For demonstrably illegal businesses, Piara Singh's broad freedom is gone — Expln 1/3 cover.
Burden of proof
Initial burden on assessee to establish bona fide business purpose (wholly and exclusively); thereafter burden shifts to Revenue to show one of the bars (capital / personal / Expln 1, 2, 3) applies. Documentary trail (board minutes, invoices, business correspondence) is decisive in scrutiny.
FA 2026 impact: No fresh FA 2026 amendment. FA 2022 had inserted Expln 3 (retrospective) expanding the 'illegal expenditure' bar to cover violations under any law in India or abroad and pharma-freebies to medical practitioners. Read with Apex Laboratories (SC).
Leading Decisions
1. Apex Laboratories (P) Ltd. v. DCIT
Citation: (2022) 442 ITR 1 (SC)
Forum: Supreme Court of India
Facts & Issue: Pharma company gave 'freebies' (gifts, travel, hospitality) to medical practitioners. Indian Medical Council (Professional Conduct) Regulations 2002 — Regulation 6.8 — prohibits doctors from accepting such gifts. Assessee claimed the expense as sales-promotion u/s 37(1).
Held / Ratio: The Supreme Court held that the expenditure is disallowed by Expln 1 to s. 37(1) — it 'is incurred for a purpose which is an offence or prohibited by law'. Even though the prohibition is on the doctor (not the pharma company), the receipt is illegal and the giving abets the violation. The Court used the doctrine that 'one cannot make a profit out of an illegality'. FA 2022 subsequently inserted Expln 3 codifying the position.
Section relevance: Landmark — controls pharma-freebies / similar regulated-recipient gifts under s. 37(1).
2. CIT v. Piara Singh
Citation: (1980) 124 ITR 40 (SC)
Forum: Supreme Court of India
Facts & Issue: Smuggler claimed deduction u/s 37(1) for the value of currency confiscated by customs authorities — treated as a 'business loss' in the illegal business.
Held / Ratio: The Supreme Court allowed the deduction. The Court held that profits of an illegal business are taxable and consequent losses/expenses, including confiscation, are deductible (since the business itself is taxed). However, expenditure that is specifically prohibited (e.g., bribes) remains outside the deduction. Note: Expln 1 to s. 37 (FA 1998) and Expln 3 (FA 2022) now significantly restrict this older line of reasoning for offence-related expenditure.
Section relevance: Foundational on taxation of illegal businesses and the historical scope of s. 37. Constrained by post-1998 Explanations.
3. Empire Jute Co. Ltd. v. CIT
Citation: (1980) 124 ITR 1 (SC)
Forum: Supreme Court of India
Facts & Issue: Jute mill purchased 'loom hours' from competitors. Revenue treated as capital (enduring benefit). Assessee claimed s. 37(1).
Held / Ratio: The Supreme Court allowed the expenditure as revenue. The Court held that 'enduring benefit' is not a conclusive test. What matters is whether the advantage affects the capital structure or the income-earning process. Here, loom hours only enabled more profitable use of existing plant — they did not augment fixed capital. The case is a watershed in the capital-vs-revenue jurisprudence under s. 37.
Section relevance: Cardinal authority on capital-vs-revenue boundary under s. 37(1); restricts the enduring-benefit doctrine.
4. Madras Industrial Investment Corpn. Ltd. v. CIT
Citation: (1997) 225 ITR 802 (SC)
Forum: Supreme Court of India
Facts & Issue: Discount on debentures — single year vs spread over life. Assessee preferred spread.
Held / Ratio: The Supreme Court permitted spread of the discount over the life of the debentures. While generally revenue expenditure is deductible in the year incurred, where the benefit endures and the discount serves the borrowed capital for several years, matching demands spreading. The Court endorsed commercial accountancy principles where the Act is silent.
Section relevance: Cardinal on 'matching' under s. 37(1) — deferred-revenue treatment.
5. Sasoon J. David & Co. (P) Ltd. v. CIT
Citation: (1979) 118 ITR 261 (SC)
Forum: Supreme Court of India
Facts & Issue: 'Wholly and exclusively' — assessee made payments which Revenue alleged were for personal benefit of directors.
Held / Ratio: The Supreme Court held that the phrase 'wholly and exclusively for purposes of business' does NOT mean 'necessarily' — an assessee may incur expenditure that, although not strictly necessary, is commercially expedient. The test is whether the expenditure was made for business purposes, judged from the assessee's vantage point and prevailing commercial considerations.
Section relevance: Defines 'wholly and exclusively' — commercial-expediency reading. Cited routinely in s. 37 litigation.
6. CIT v. Walchand & Co.
Citation: (1967) 65 ITR 381 (SC)
Forum: Supreme Court of India
Facts & Issue: Whether reasonableness of expenditure is a ground for disallowance under s. 37(1).
Held / Ratio: The Supreme Court held that the Income-tax officer cannot disallow expenditure merely on the ground that he considers it excessive or unreasonable. So long as the expenditure is laid out wholly and exclusively for business, the quantum is for the businessman, not the Revenue. (This is now subject to specific anti-avoidance provisions like s. 40A(2) for related-party excess.)
Section relevance: Cardinal on quantum-of-expenditure neutrality of Revenue under s. 37 — subject to specific overrides.
7. CIT v. T.V. Sundaram Iyengar & Sons Ltd.
Citation: (1996) 222 ITR 344 (SC)
Forum: Supreme Court of India
Facts & Issue: Trade advances / deposits no longer claimed by counterparties — written back to P&L. Question whether such write-back is income.
Held / Ratio: The Supreme Court held that where trading liability ceases (lapse, time-bar, write-back) and the amount was originally received in the course of business, the write-back is income. The Court drew on 'change of character' from advance to income. Often cited in conjunction with s. 41(1) and s. 37 disallowances.
Section relevance: Cardinal on character-change of business advances under PGBP framework.
— End of Section 37 Case-Law Note —